Navigation Links
Curemark to Present at BioPharm America™ 2010
Date:8/23/2010

RYE, N.Y., Aug. 23 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, will present at BioPharm America™ 2010, to be held September 15-17 in Boston at the Marriott Boston Copley Place, the company announced.

Dr. Joan Fallon, Curemark's founder and CEO, will provide an overview of the company's enzyme replacement therapy targeted to autism. Curemark is now in Phase III clinical trials for CM-AT, its autism treatment.  She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the U.S. Food and Drug Administration (FDA) for the use of the company's compound CM-4612 to treat attention deficit hyperactivity disorder (ADHD).  The FDA has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of CM-4612 in the treatment of ADHD.

"We are very pleased to be able to give a presentation at this year's BioPharm America," Fallon said.  "We welcome the opportunity to discuss our momentum with therapies that address neurological conditions for which there are currently no viable, physiologically-based treatments."  

CM-AT, Curemark's autism treatment, targets enzyme deficiencies in autistic children that affect the availability of amino acids, the building blocks of chemicals essential for brain function.  The company is currently conducting Phase III CM-AT trials at 13 sites nationwide with a planned total of 170 children.  If approved, CM-AT, which has been granted Fast Track status from the FDA, will be one of the first therapies to address the underlying physiology of autism.  

Organized by EBD Group, a leading partnering firm for the global life sciences industry, BioPharm America is intended as a forum where biotech and pharma executives from around the world can meet, and identify and enter strategic relationships.  BioPharm America 2010 is the third annual international partnering conference.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):